Lupus Nephritis Clinical Trials in Houston, Texas

6 studies are recruiting for lupus nephritis in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

   The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided precision-dosing of MMF (MMFPK; MMF dosed twice daily …

   Stage

   Phase 2

   Ages

   8 to 20

   Site

   Baylor College of Medicine Pediatric Immunology Allergy Rheumatology, Houston, Texas

   Locations

   19 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT05538208 on ClinicalTrials.gov

2. RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   23 in total

   Run by

   Cabaletta Bio

   See if you can join NCT06121297 on ClinicalTrials.gov

3. PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

   The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).

   Stage

   Phase 4

   Ages

   18 to 75

   Site

   Northwest Houston Arthritis Center, Houston, Texas

   Locations

   27 in total

   Run by

   Aurinia Pharmaceuticals Inc.

   See if you can join NCT07611214 on ClinicalTrials.gov

4. Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

   The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   Prolato Clinical Research Center, Houston, Texas

   Locations

   103 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT05268289 on ClinicalTrials.gov

5. A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

   This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Nkarta Investigational Site, Houston, Texas

   Locations

   19 in total

   Run by

   Nkarta, Inc.

   See if you can join NCT06557265 on ClinicalTrials.gov

6. Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

   The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the dis…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   2 in total

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06434363 on ClinicalTrials.gov